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A B S T R A C T
Background: Type 2 diabetes mellitus (T2DM) is associated with hypofibrinolysis and increased factor XIII-
mediated α2-antiplasmin incorporation into the fibrin clot. It is unclear whether there are sex-related differences
in α2-antiplasmin incorporation in relation to impaired clot lysis in T2DM.
Aim: We investigated α2-antiplasmin incorporation into fibrin clots as a determinant of clot lysability in patients
of both sexes with T2DM.
Methods: In a group of 113 T2DM patients, 54 (47.8%) of which were women, we investigated α2-antiplasmin
incorporation using an in-house sandwich enzyme-linked immunoassay and plasma clot lysis by turbidimetry,
along with fibrinogen and thrombin generation using calibrated automated thrombogram and factor XIII ac-
tivity.
Results: Female patients had 15.2% greater α2-antiplasmin incorporation into the fibrin clot (p=0.008) and
slightly higher plasma α2-antiplasmin concentration (p=0.005) along with 8.4% longer time to 50% lysis
(Lys50MA, p=0.012) compared with men. Female patients had enhanced thrombin generation represented by
shorter lag phase (p=0.042), shorter time to peak (p=0.033), and higher endogenous thrombin potential
(p=0.003) compared with men, while factor XIII activity was comparable between sexes (p=0.085). On
multivariate regression, patient sex and glycated hemoglobin (HbA1c) level were the predictors of α2-anti-
plasmin incorporation in the entire patient group, while α2-antiplasmin incorporation was associated with
Lys50MA, as were fibrinogen, male sex and body-mass index.
Conclusions: This study suggests that a more compromised fibrinolysis in diabetic women when compared with
men could be in part mediated by increased α2-antiplasmin incorporation into the fibrin.
1. Introduction
Compelling evidence indicates that patients with type 2 diabetes
mellitus (T2DM) have a prothrombotic fibrin clot phenotype char-
acterized by the formation of compact fibrin meshwork of reduced
permeability and lysability [1,2]. Several studies have shown that fi-
brinolysis is more compromised in female patients with T2DM when
compared with males [3,4]. Mechanisms underlying this observation
are poorly understood.
Factors known to be involved in impaired fibrinolysis in T2DM in-
clude increased levels of plasminogen-activator inhibitor (PAI-1) and
thrombin-activatable fibrinolysis inhibitor (TAFI) and a more compact
clot structure associated with elevated fibrinogen concentrations, along
with increased incorporation of antifibrinolytic proteins into the clot,
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such as complement C3 and α2-antiplasmin [2]. In 2012, Alzahrani
et al. showed in a large study that women with T2DM have a more
compromised fibrinolysis when compared to men with T2DM assessed
using a plasma-based assay [3]. Furthermore, impaired fibrinolysis in
women was not attributable to fibrinogen or PAI-1 levels, but rather to
elevated body-mass index (BMI) and low levels of high-density lipo-
protein cholesterol (HDL-C) [3]. Patients with cardiovascular disease
(CVD), among whom 20% also had T2DM, also showed sex-related
differences in plasma clot lysability which were not related to levels of
fibrinogen and inflammatory markers such as C-reactive protein (CRP),
complement C3 and interleukin 6 (IL-6) [4]. To the best of our
knowledge, the role of α2-antiplasmin incorporation in sex-associated
alterations to fibrin clot properties has not yet been studied.
The major fibrinolysis inhibitor, α2-antiplasmin (67 kDa), is syn-
thesized in the liver and circulates at a concentration of approximately
70 μg/mL (1 μM) and has a half-life of approximately 2.6 days [5]. α2-
antiplasmin is cross-linked by glutamine 14 (or glutamine 2 in the Asn-
α2-antiplasmin isoform) to lysine 303 of the fibrinogen Aα-chain by
thrombin-activated factor XIII (FXIII) [6]. Using a purified-fibrinogen
clot lysis model, diabetic patients without CVD have been demonstrated
to incorporate more α2-antiplasmin into fibrin when compared to pa-
tients without T2DM, without any sex-related differences [7].
Recently, increased α2-antiplasmin incorporation has been shown
using a plasma-based clotting assay in young patients with diabetes
(unspecified type) following myocardial infarction (MI) or ischemic
stroke [8]. It is unknown whether there are any differences in this re-
action between men and women with T2DM. We hypothesized that
increased α2-antiplasmin incorporation might contribute to a more
prothrombotic fibrin clot phenotype in women with T2DM.
We aimed to investigate α2-antiplasmin incorporation into fibrin in
relation to plasma fibrin clot lysis in females and males with T2DM.
Moreover, we sought to identify factors which affect α2-antiplasmin
incorporation in T2DM.
2. Materials and methods
2.1. Study design
In this cross-sectional study, we enrolled Caucasian patients aged
≥18 years who fulfilled the World Health Organization criteria for
T2DM [9]. Patients were recruited in Cracow, Poland, between October
2016 and July 2017. This patient cohort was presented previously [10].
Briefly, the exclusion criteria were as follows: signs of acute infection,
arterial or venous thromboembolic events within the previous six
months, current anticoagulant therapy, known cancer, recent trauma or
surgery, autoimmune diseases, and pregnancy. Demographic and clin-
ical data, including the time since T2DM diagnosis, were collected upon
enrollment. Comorbidities were defined in a previous study [10]. The
Bioethics Committee at the Jagiellonian University Medical College
approved the study. All subjects provided written, informed consent.
2.2. Laboratory investigations
Fasting blood samples were obtained from the antecubital vein be-
tween 6 and 8 AM. Fasting glucose, white blood cells count, he-
moglobin, platelet count, creatinine, albumin-to-creatinine ratio (ACR),
total cholesterol, low-density-lipoprotein cholesterol (LDL-C), HDL-C,
and triglycerides were assayed by routine laboratory techniques.
Estimated glomerular filtration rate (eGFR) was calculated using the
Chronic Kidney Disease Epidemiology Collaboration equation. High-
sensitivity C-reactive protein (hs-CRP) was measured by a latex-en-
hanced turbidimetric immunoassay using a Cobas 6000 analyzer
(Roche Diagnostics, Mannheim, Germany). Glycated hemoglobin
(HbA1c) was measured by high-performance liquid chromatography
using the Variant II Turbo analyzer (Hercules, CA, USA).
2.3. Coagulation and fibrinolysis parameters
Blood samples were mixed with 3.2% sodium citrate (9:1), cen-
trifuged for 20min and plasma was stored at −80 °C. Fibrinogen was
determined using the von Clauss method. Plasminogen and α2-anti-
plasmin activities were measured by chromogenic assays (Berichrom,
Siemens, Munich, Germany). Commercially available enzyme-linked
immunosorbent assays (ELISA) were used to measure PAI-1 antigen
(Hyphen, Neuville-sur-Oise, France), TAFI (Hyphen), and interleukin-6
(IL-6; R&D Systems, Minneapolis, MN, USA). Activity of FXIII was
measured by the ammonia release assay [11] using a commercially
available reagent kit (REA-chrom FXIII kit, Reanal-ker, Budapest,
Hungary; reference range: 69–143%, coefficient of variation: 3.8%).
2.4. Calibrated automated thrombogram
Assessment of the thrombin generation profile was performed as
previously described [12]. Citrated plasma samples were thawed at
37 °C for 3min and 5mg/ml corn trypsin inhibitor was immediately
added to achieve a 0.1mg/ml final concentration. Eighty μl of each
plasma sample was added to a 96-well plate followed by addition of
relipidated tissue factor [13] at a final concentration of 5 pM. The
fluorogenic substrate used was benzyloxycarbonyl-Gly-Gly-Arg-7-
amido-4methylcoumarin·HCl (Z-GGR-AMC) (Bachem, Torrance, CA,
USA). Twenty μl of a 2.5mM Z-GGR-AMC/90mM CaCl2 solution in
HEPES-buffered saline was added to plasma samples to achieve final
concentrations of 417 μM and 15mM, respectively. A 3min incubation
period at 37 °C followed to allow recalcification of the plasma. Twenty
μl of a 120 μM phospholipid vesicle solution (25% dioleoyl-sn-glycero-
3-phospho-L serine and 75% 1,2-dioleoyl-sn-glycero-3-phosphocholine)
(Avanti Polar Lipids, Inc., Alabaster, Al) in HEPES-buffered saline was
then added to plasma samples to achieve a final concentration of 20 μM,
thus initiating thrombin generation. Fluorescence readings began im-
mediately and hydrolysis of the AMC (7-amino-4-methylcoumarin)
substrate (at 370 nm excitation and 460 nm emission wavelengths) was
followed over a 3600 s period. Changes in fluorescence were converted
to thrombin concentration using a calibration curve built by sequential
dilutions of human thrombin (Haematologic Technologies, Inc., Essex
Junction, VT). Human thrombin was produced in-house [14]. We used
a plate reader, the BioTek Synergy 4 and the Gen5 plate reader software
(BioTek, Winooski, VT, USA) to generate the following parameters: (a)
time following addition of the trigger until initiation of thrombin gen-
eration (lag phase, seconds); (b) peak thrombin (nmol/l); (c) time to
reach the peak (time-to peak, seconds); (d) area under the curve, de-
fined as endogenous thrombin potential (ETP, nmol/l thrombin*se-
conds).
2.5. Clot permeability and lysability
Fibrin clot structure and lysability were evaluated by a turbidi-
metric method as previously described by Carter et al. [15]. Briefly,
25 μl of citrated plasma, mixed with 12.5 ng of recombinant tissue
plasminogen activator (tPA, Actilyse, Boehringer Ingelheim, Biberach,
Germany) in 75 μl of a lysis buffer (0.05mol/l Tris-HCl, 0.1mol/l NaCl,
pH 7.4), and 50 μl of activation mix (final concentrations: 0.03 U/ml
thrombin [Merck KGaA, Darmstadt, Germany], and 7.5 mmol/l calcium
in assay buffer), were added to each well of the 96-well plate using a
multichannel pipette at 15 s intervals. Plates were read at 340 nm every
12 s during a period of 1 h in a microplate reader (Sunrise Reader,
Tecan, Maennedorf, Switzerland). The following parameters were re-
corded: a) Clot maximum absorbance (arbitrary units, au) indicating
network density, b) Lysis time (Lys50MA, seconds) corresponding to
time from full clot formation to 50% lysis, indicating fibrinolytic po-
tential; c) Time to complete lysis (LysT, seconds) indicating the time
from clot maximum absorbance to the time for absorbance values to
return to baseline; d) Lysis area (au), reflecting the balance between
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clot formation and lysis. Differences in clot lysis time were confirmed
using protocol previously described by Pieters et al. with tPA con-
centration of 18–20 ng/ml [16]. Clot lysis time was calculated as the
time from the midpoint, from clear to maximum turbidity, to the
midpoint in the transition from maximum turbidity to the final baseline
turbidity.
2.6. α2-antiplasmin incorporation assay
The extent of α2-antiplasmin incorporation into fibrin clots was
determined using an assay described previously [17]. Briefly, α2-anti-
plasmin antigen levels of citrated plasma samples were measured using
an in-house ELISA that detects all forms of α2-antiplasmin and is not
influenced by the presence of plasmin-antiplasmin complexes (re-
ference range: 48–85mg/l). Next, 200 μl of citrated plasma samples
were clotted with 2 U/l human thrombin (Sigma-Aldrich, St. Louis, MO,
USA) and 12.5mM CaCl2 at 37 °C for 30min and the amount of non-
clot-bound α2-antiplasmin was determined from the serum of the clots,
obtained by a 10min centrifugation. The extent of α2-antiplasmin in-
corporation was calculated based on the difference in the amount of α2-
antiplasmin between plasma and serum samples using the following
formula: extent of α2-antiplasmin incorporation (mg/l)= amount of
α2-antiplasmin in plasma (mg/l)− amount of α2-antiplasmin in serum
(mg/l).
2.7. Statistical analysis
Categorical variables were presented as numbers (percentages) and
compared using Fisher's exact test for 2×2 contingency tables and
Pearson's chi–squared test for other tables. Continuous variables were
expressed as mean ± standard deviation or median and interquartile
range. Normality was assessed by the Shapiro–Wilk test. Differences
between groups were compared using the Student's t-test for normally
distributed continuous variables or the Mann–Whitney U test for
non–normally distributed continuous variables. Pearson's correlation
coefficient was calculated for normally distributed variables while
Spearman's correlation coefficient was determined for non-normally
distributed variables. Univariate linear regression model was used to
assess the coefficient of determination (R2) representing the contribu-
tion of α2-antiplasmin incorporation to the variance of Lys50MA.
Backward stepwise multivariate regression models were used to in-
vestigate associations between (1) α2-antiplasmin incorporation and
metabolic determinants (plasma glucose, HbA1c, diabetes duration,
total cholesterol and HDL-C) and determinants associated with T2DM
complications (CVD, albuminuria and serum creatinine); (2) Lys50MA
and coagulation and fibrinolysis components (fibrinogen, plasminogen,
PAI-1, TAFI, FXIII and plasma α2-antiplasmin) and α2-antiplasmin in-
corporation. All variables which were non-normally distributed were
log-transformed before inclusion in the model. The effect of each
variables was characterized in a regression model using 95% confidence
interval (CI) for the regression coefficients with p-values. Two–sided
p–values< 0.05 were considered statistically significant. All calcula-
tions were done with Statistica (v. 12.5, StatSoft, Inc., Tulsa, OK, USA)
and R package [18].
3. Results
3.1. General characteristics of men and women
Female patients did not differ from males in regard to age and BMI,
however, they weighed less (Table 1). As few as 2 (3.7%) female pa-
tients were of reproductive age, while the rest of the patients were
postmenopause. One (1.9%) woman was receiving hormone replace-
ment therapy, while 2 (3.7%) other patients had received it in the past.
Female patients had slightly lower hemoglobin, higher platelet count,
higher total cholesterol and higher HDL-C compared with male subjects
(Table 1). In terms of coagulation and fibrinolysis parameters, female
patients had lower PAI-1 compared with men, while fibrinogen, plas-
minogen and TAFI were similar in both sexes (Table 2). Inflammation
markers, CRP and IL-6, were comparable between sexes (Table 2). Fe-
male sex was associated with enhanced thrombin generation re-
presented by shorter time-to-peak (−5.3%, p=0.033) and higher ETP
(+14.7%, Table 2). Factor XIII activity was comparable between sexes
(Table 2).
Women had increased α2-antiplasmin incorporation into the clot
(27.50 [23.19–32.40] vs. 23.88 [20.79–28.60] mg/l, p=0.008,
Fig. 1A), which was also seen after adjustment for BMI (p=0.005).
Moreover, women displayed higher plasma α2-antiplasmin concentra-
tion (64.70 [60.55–71.10] vs. 60.91 [55.23–66.50] mg/l, p=0.005)
and increased α2-antiplasmin activity (107.0 [103.0–113.0] vs. 99.0
[94.0–106.0] %, p < 0.001) when compared with men. Female sex
was associated with impaired fibrinolysis represented by longer
Lys50MA (Fig. 1B, Table 2). Sex did not affect LysT (Table 2). Prolonged
clot lysis time in women with T2DM when compared with men with
T2DM was confirmed using assay by Pieters et al. (128.0 [104.0–169.0]
vs. 116.5 [88.7–141.7] min, p=0.029).
3.2. Factors affecting α2-antiplasmin incorporation
When female and male patients with T2DM were analyzed together,
patients with α2-antiplasmin incorporation in the top quartile
(≥29.79mg/l) did not differ from the remainder with regard to age,
BMI, or time since T2DM (data not shown). α2-antiplasmin in-
corporation in the top quartile was associated with slightly decreased
hemoglobin (133 ± 14 vs. 139 ± 12 g/l, p=0.043), elevated platelet
count (260 ± 64 vs. 221 ± 58×109/l, p=0.007) and increased
fasting glucose (8.0 [6.8–9.1] vs. 6.9 [5.9–8.1] mmol/l, p=0.025)
when compared with the remainder. Patients with α2-antiplasmin in-
corporation in the top quartile had higher fibrinogen (+11.8%,
p=0.010) and plasminogen (+10.7%, p=0.002) compared with the
remainder (Table 2). α2-antiplasmin incorporation was correlated with
its activity (r=0.409, p < 0.001), fibrinogen (r=0.229, p=0.016),
and FXIII activity (r=0.449, p < 0.001). FXIII activity was also in-
creased in patients with α2-antiplasmin incorporation in the top
quartile when compared with the remainder (Table 2). In terms of
thrombin generation, patients with α2-antiplasmin incorporation in the
top quartile had markedly higher peak thrombin (+30.2%, p=0.018)
and slightly elevated ETP (+12.2%, p=0.035) when compared with
the remainder (Table 2).
In the multivariate regression model, sex and HbA1c level were
predictors of α2-antiplasmin incorporation (Fig. 2A).
Prior MI and CVD did not associate with α2-antiplasmin in-
corporation (p=0.80 and p=0.88, respectively). Treatment with
metformin, sulfonylurea, insulin or other medications did not affect α2-
antiplasmin incorporation (data not shown).
3.3. α2-antiplasmin incorporation and clot lysis time
When female and male patients with T2DM were analyzed together,
prolonged lysis time as evidenced by increased Lys50MA (+23.0%,
p < 0.001), LysT (+11.0%, p=0.004) and lysis area (+7.1%,
p=0.028, Table 2) were detected in patients with α2-antiplasmin in-
corporation in the top quartile when compared with the remainder. In
univariate linear regression, α2-antiplasmin incorporation accounted
for 22.6% of the total variance in Lys50MA (p < 0.001). In a multi-
variate model adjusted for age, sex and BMI, α2-antiplasmin in-
corporation was found to be a predictor of Lys50MA (whole model
R2=0.32, Fig. 2B). According to the following equation utilizing log-
transformed variables as appropriate: Log(Lys50MA)= 0.31*log(In-
corporated α2-antiplasmin)+ 0.24*log(fibrinogen)-0.008*log(PAI-1)-
0.08*male sex+0.29*log(BMI)+ 3.81, diabetic females had 8% higher
Lys50MA when compared with men.
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Table 1
Comparison of demographic data, comorbidities, medications and routine laboratory investigations between female and male patients with type 2 diabetes (T2DM).
Variable All
(n=113)
Female
(n=54, 47.8%)
Male
(n=59, 52.2%)
p-Value
Age, years 63.8 ± 8.2 64.6 ± 7.7 62.9 ± 8.6 0.28
Weight, kg 89.0 (79.5–102.0) 81.0 (73.0–90.0) 101.0 (85.0–114.0) < 0.001
BMI, kg/m2 32.0 (29.4–37.2) 32.0 (29.4–35.9) 32.3 (29.1–37.9) 0.58
Obesity, n (%) 76 (67.3) 36 (66.7) 40 (67.8) 1.0
Current smoking 16 (14.2) 4 (7.4) 12 (20.3) 0.061
Family history of CVD 31 (27.4) 21 (38.9) 10 (16.9) 0.011
T2DM data
HbA1c, % 6.9 (6.1–8.2) 6.7 (6.0–7.9) 7.7 (6.1–8.4) 0.10
Time since T2DM diagnosis, years 7.0 (3.0–15.0) 8.0 (3.0–17.0) 7.0 (3.0–12.0) 0.20
Comorbidities, n (%)
Arterial hypertension 105 (92.9) 52 (96.3) 53 (89.8) 0.28
CVD 54 (47.8) 22 (40.7) 31 (52.5) 0.26
Previous MI 21 (18.6) 7 (13.0) 14 (23.7) 0.16
Heart failure 9 (8.0) 4 (7.4) 5 (8.5) 1.0
Medication, n (%)
Aspirin 74 (65.4) 33 (61.1) 41 (69.5) 0.43
Clopidogrel 9 (7.9) 4 (7.4) 5 (8.5) 1.0
β-blocker 82 (72.6) 43 (79.6) 39 (66.1) 0.14
Statin 75 (66.4) 38 (70.4) 37 (62.7) 0.43
ACEI 63 (55.8) 31 (57.4) 32 (54.2) 0.85
ARB 35 (31.0) 15 (27.8) 20 (33.9) 0.54
Calcium antagonist 49 (43.4) 25 (46.3) 24 (40.7) 0.57
Thiazide 37 (32.7) 17 (31.5) 20 (33.9) 0.84
Indapamide 26 (23.0) 15 (27.8) 11 (18.6) 0.27
Loop diuretics 21 (18.6) 11 (20.4) 10 (16.9) 0.81
Antidiabetic treatment, n (%)
No hypoglycemic drugs 8 (7.1) 1 (1.9) 7 (11.9) 0.09
Oral drug (metformin, sulfonylurea or both) 60 (53.1) 32 (59.3) 28 (47.5)
Insulin 13 (11.5) 4 (7.4) 9 (15.3)
Insulin and oral drug 32 (28.3) 17 (31.5) 15 (25.4)
Laboratory investigations
Fasting glucose, mmol/l 7.30 (6.00–8.50) 6.80 (6.00–7.90) 7.40 (5.95–9.10) 0.10
WBC, ×106/l 7.4 ± 1.6 7.6 ± 1.7 7.3 ± 1.6 0.30
Hemoglobin, g/l 138 ± 13 132 ± 12 142 ± 12 <0.001
Platelet count, ×109/l 231.9 ± 61.4 263.4 ± 55.2 203.1 ± 52.3 < 0.001
ACR, mg/g creatinine 7.6 (3.98–21.9) 5.70 (3.94–13.00) 9.63 (4.42–35.80) 0.09
ACR ≥30mg/g creatinine 21 (18.6) 6 (11.1) 15 (25.4) 0.06
(continued on next page)
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4. Discussion
Our study shows that more compromised fibrinolysis in T2DM fe-
male patients, compared with T2DM males, is associated with increased
α2-antiplasmin incorporation into the clot. This difference was ob-
served despite similar BMI, HbA1c with no association with con-
comitant CVD. Elevated plasma α2-antiplasmin incorporation in female
diabetic patients was accompanied by increased thrombin generation,
possibly leading to faster FXIII activation, responsible for α2-anti-
plasmin cross-linking to fibrin. Our findings provide additional in-
formation on the regulation of fibrinolysis in T2DM, highlighting the
complex gender-related differences.
To the best of our knowledge, we are the first group to observe that
α2-antiplasmin incorporation is associated with impairment of fi-
brinolysis in female patients with T2DM. It is unclear which
mechanisms could be responsible for the increased α2-antiplasmin in-
corporation in females when compared to males. Enhanced cross-
linking of commercially available human α2-antiplasmin observed in
experiments with fibrinogen purified from plasma of uncontrolled
T2DM patients, indicated that fibrinogen and fibrin glycation increases
incorporation of normal α2-antiplasmin [7]. It seems rather unlikely
that HbA1c determines the differences in α2-antiplasmin incorporation
as both HbA1c and sex were independent predictors of α2-antiplasmin
incorporation in the multivariate regression model. Metformin, which
has been reported to exert several effects on prothrombotic mechanisms
in T2DM [19,20], did not associate with α2-antiplasmin incorporation
in the present study. To our knowledge, there is no data on the glyca-
tion of α2-antiplasmin molecule, and whether it occurs in the proximity
of the glutamine residue responsible for cross-linking with fibrinogen.
N-terminus cleavage by soluble fibroblast activation protein (sFAP)
Table 1 (continued)
Variable All
(n=113)
Female
(n=54, 47.8%)
Male
(n=59, 52.2%)
p-Value
eGFR, ml/min/m2 84.0 (69.0–92.0) 79.0 (68.0–92.0) 85.0 (72.0–93.0) 0.15
eGFR ≤60ml/min/1.73m2 17 (15.0) 11 (20.4) 6 (10.2) 0.19
Total cholesterol, mmol/l 4.20 (3.50–5.30) 4.50 (3.88–5.30) 3.92 (3.23–5.20) 0.032
LDL-C, mmol/l 2.50 (1.80–3.50) 2.70 (2.15–3.40) 2.45 (1.63–3.50) 0.13
HDL-C, mmol/l 1.20 (1.0–1.50) 1.40 (1.16–1.70) 1.05 (0.87–1.30) < 0.001
Triglycerides, mmol/l 1.50 (1.17–2.00) 1.50 (1.16–1.80) 1.67 (1.18–2.30) 0.11
Categorical variables are presented as numbers (percentages) and were compared by the Fisher's exact test for 2× 2 contingency tables. Continuous variables are
expressed as mean ± standard deviation or median and interquartile range. Differences between groups were compared using the Student's t-test for normally
distributed continuous variables or the Mann–Whitney U test for non–normally distributed continuous variables.
BMI denotes body-mass index; HbA1c, glycated hemoglobin; CVD, cardiovascular disease; MI, myocardial infarction; ACEI, angiotensin-converting enzyme inhibitor;
ARB, angiotensin receptor blocker; eGFR, estimated glomerular filtration rate; WBC, white blood cells; ACR, albumin-to-creatinine ratio; LDL-C, low-density lipo-
protein cholesterol; HDL-C, high-density lipoprotein cholesterol.
Table 2
Comparison of fibrin clot components and phenotype between female and male patients.
Variable Female
(n=54, 47.8%)
Male
(n=59, 52.2%)
p-Value Patients with α2-antiplasmin incorporation p-Value
≥29.79mg/dl
(n=28, 25.2%)
< 29.79mg/dl
(n=86, 74.8%)
Coagulation and fibrinolysis components
Fibrinogen, g/l 3.40 (3.06–4.00) 3.49 (3.17–3.80) 0.94 3.80 (3.31–4.00) 3.40 (3.09–3.80) 0.010
Plasminogen, % 109.5 (101.0–118.0) 109.0 (99.0–124.0) 0.70 118.5 (106.5–125.0) 107.0 (99.0–117.0) 0.002
PAI-1, ng/ml 34.80 ± 6.26 37.91 ± 7.62 0.020 36.1 ± 6.67 36.7 ± 7.30 0.68
TAFI, % 104.5 (95.0–114.0) 101.0 (88.0–113.0) 0.10 101.20 ± 13.80 104.2 ± 14.02 0.34
Factor XIII activity, % 134.3 ± 36.78 122.09 ± 37.25 0.085 150.50 ± 31.62 120.90 ± 36.72 <0.001
Inflammation markers
C-reactive protein, mg/l 3.30 (1.47–5.60) 1.88 (1.08–3.70) 0.78 3.20 (1.55–5.70) 2.1 (1.10–4.40) 0.17
Interleukin 6, pg/ml 4.00 (2.76–5.70) 3.55 (2.43–6.00) 0.61 4.10 (2.81–5.30) 3.50 (2.20–6.70) 0.87
Thrombin generation
Lag phase, s 940 (729–1216) 1067 (859–1444) 0.042 1024 (716–1222) 1008 (839–1359) 0.12
Peak thrombin, nmol/l 116.0 (96.9–159.3) 117.3 (86.6–153.0) 0.41 148.0 (104.0–167.9) 113.7 (86.7–142.1) 0.018
Time-to-peak, s 1330 (1015–1691) 1405 (1171–2022) 0.033 1245 (998–1684) 1430.5 (1164.0–1911.5) 0.056
ETP, nM*s 114,474 ± 26,429 99,796 ± 26,907 0.004 115,870 ± 26,826 103,314 ± 26,828 0.035
Clot lysis parameters
MaxAbsL, au 0.40 (0.33–0.40) 0.38 (0.33–0.40) 0.97 0.40 (0.36–0.50) 0.40 (0.33–0.40) 0.047
Lys50MA, s 413 (377–480) 380 (338–439) 0.012 471 (401–555) 383 (345–435) <0.001
LysT, s 795 (690–878) 743 (660–833) 0.15 825 (788–930) 743 (653–833) 0.004
Lysis area, au 986 (864–1101) 994 (895–1221) 0.22 1029 (976–1238) 961 (864–1105) 0.028
Data were presented as mean ± standard deviation or median and interquartile range. Groups were compared using the Student's t-test for normally distributed
continuous variables or the Mann–Whitney U test for non–normally distributed continuous variables. PAI-1 denotes plasminogen activator inhibitor 1; TAFI,
thrombin activatable fibrinolysis inhibitor; ETP, endogenous thrombin potential; MaxAbsL, maximum clot absorbance in lysis assay; Lys50MA, time to 50% lysis; LysT,
time to complete lysis.
Data on α2-antiplasmin incorporation and Lys50MA were available for 111 and 110 patients, respectively.
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occurs in the proximity of this glutamine, resulting in increased velocity
of α2-antiplasmin cross-linking to fibrin [5]. While reduced activity of
sFAP in healthy women when compared to men has been previously
reported [21], the association between sex and sFAP level in T2DM
requires verification in further studies. BMI has been identified as an
anthropometric factor associated with prothrombotic fibrin clot in
diabetic women [3]. BMI predicted α2-antiplasmin incorporation in our
study, when analyzing women and men together. Obesity exerts several
effects on the thrombotic milieu associated with insulin resistance.
Since there was no difference between sexes with regard to BMI, it is
unlikely that obesity-related phenomena affected the relationship be-
tween prolonged clot lysis and increased α2-antiplasmin cross-linking
in women when compared with men.
Another important finding of our study is the positive association
between α2-antiplasmin incorporation and clot lysability as determined
by the turbidimetric assay in T2DM patients. The turbidimetric assay
provides dynamic analysis of clot lysis and global assessment of the
fibrin phenotype and has been successfully used to study fibrinolysis in
T2DM [3,4], metabolic syndrome [15] and myocardial infarction [22].
The only study on turbidimetric lysis time in relation to α2-antiplasmin
incorporation involved type 1 diabetes, and the authors did not identify
any sex-related differences [23]. In our study increased α2-antiplasmin
incorporation in female T2DM patients was associated with prolonged
Lys50MA with no sex-related differences for LysT. Clot lysis time as-
sessment with lower concentration of tPA allowed to fully appreciate
the difference in clot lysis time between women and men with T2DM.
Unexpectedly, in contrast to previous data [3], we found that female
T2DM patients had lower PAI-1 when compared with men, which could
be attributed to the markedly lower weight of female patients [24]. PAI-
1 is an important fibrinolysis inhibitor responsible for 40% of the
Fig. 1. Comparison of α2-antiplasmin incorporation (A) and lysis time (Lys50MA, B) between female (black dots) and male (white dots) patients with type 2 diabetes
mellitus (T2DM). Horizontal line represents median value. Data on α2-antiplasmin incorporation and Lys50MA were available for 111 and 110 patients, respectively.
Fig. 2. Predictors of α2-antiplasmin incorporation (A) and
lysis time (Lys50MA, B) in patients with type 2 diabetes mel-
litus. Results are shown as multivariable regression coeffi-
cients with 95% confidence interval (CI). Due to the im-
portance of the plasminogen activator inhibitor-1 (PAI-1) for
fibrinolysis, PAI-1 was retained in the regression model, al-
though insignificant. HbA1c denotes glycated hemoglobin;
BMI, body-mass index.
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variation in clot lysis time determined by Lisman method in general
population [25] and up to 13% of the variation in turbidimetric lysis
variables investigated by Carter method among healthy subjects and
patients with metabolic syndrome [15]. PAI-1 and α2-antiplasmin in-
hibit fibrinolysis by different mechanisms and different are the re-
lationships between antigen and activity among those two inhibitors.
PAI-1 is released from platelets and the endothelium and inhibits tPA
[26]. In plasma, PAI-1 activity and PAI-1 antigen are correlated with
the coefficient of 0.8, and approximately two thirds of the PAI-1 antigen
is functionally active [27]. α2-antiplasmin, secreted by the liver, is
cross-linked to the fibrin clot and inhibits plasmin [26]. Decreased PAI-
1 in the female patients with type 2 diabetes mellitus when compared
with male patients might suggest attenuated inhibition of tissue plas-
minogen activator, leading to higher plasmin generation which is in-
hibited by the increased cross-linking of plasma α2-antiplasmin into the
fibrin clot. These changes may result in prolonged clot lysis time. We
observed that α2-antiplasmin incorporation did not relate to the clot
maximum absorbance, which was comparable among sexes, being as-
sociated with similar fibrinogen concentrations in patients included in
our study.
Analysis of thrombin generation profiles in T2DM yielded inter-
esting observations in the context of fibrinolysis. Patients with T2DM
have been reported by several groups to display enhanced thrombin
generation in comparison to controls [28–30], and a more hypercoa-
gulable clot has been reported in apparently healthy female subjects as
compared with men [4]. Since 90% of α2-antiplasmin incorporation is
FXIII-dependent [8], and FXIII becomes activated by thrombin [6], it
would be expected that women with T2DM who have increased α2-
antiplasmin incorporation could demonstrate increased thrombin gen-
eration as compared with men. Indeed in the present study, female
diabetic patients were characterized by faster formation of the total
amounts of thrombin (which can be generated in a plasma sample)
when compared with male subjects. Women have been reported to have
elevated platelet count when compared with men [31,32], while pla-
telet-dependent thrombin generation has been reported to be higher in
patients with poorly glycemic-controlled T2DM when compared with
healthy subjects [33]. Based on those reports we suspect that faster
formation of thrombin might result in faster FXIII activation and ulti-
mately to different clot structure, including increased α2-antiplasmin
incorporation.
Our study had several limitations. First, the sizes of study groups
were limited, although the study was sufficiently powered to show the
difference in Lys50MA and α2-antiplasmin incorporation among sexes.
Secondly, assessment of plasma fibrin ex vivo eliminated the potential
influence of platelet or endothelial factors on clot properties. It cannot
be ruled out that in platelet-rich plasma the importance of the elevated
α2-antiplasmin would be relatively lower given the high PAI-1 content
secreted from the platelets [34,35]. Using clot compaction [36] could
amplify the difference in α2-antiplasmin incorporation between women
and men with T2DM. Finally, due to the cross-sectional design of the
study, it provided only single assessment of associations between clot
components and its phenotype. Our investigation was meant to be a
hypothesis-generating study and possible mechanisms of observed re-
lationships should be established in further studies.
In summary, our findings increase the current knowledge on factors
affecting efficiency of fibrinolysis in patients with T2DM, showing an
association between compromised fibrinolysis and increased α2-anti-
plasmin incorporation into the fibrin clot in female patients when
compared with male subjects. Further studies are required to elucidate
the mechanisms underlying this association.
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